GeoVax was using its HHS contract to develop its next-generation multi-antigen COVID-19 vaccine, which is in Phase IIb ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

Peer-Reviewed Data Reinforces GeoVax's Multi-Antigen Strategy With GEO-CM02 and Supports Advancement of GEO-CM04S1 Clinical ...

Despite the PNG award termination, GeoVax anticipates a milestone-rich 2025 across its portfolio. The Company will continue to engage with government and industry partners, pursue clinical trial ...

Roth Capital lowered the firm’s price target on GeoVax Labs (GOVX) to $18 from $20 and keeps a Buy rating on the shares after the company ...

D. Boral Capital lowered the firm’s price target on GeoVax Labs (GOVX) to $14 from $18 and keeps a Buy rating on the shares.

GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing vaccines with a current market capitalization of $19.78 million, announced today that its shareholders have ...

GEOVAX LABS ($GOVX) is expected to release its quarterly earnings data on Thursday, March 27th after market close, per Finnhub. Analysts are expecting revenue of ...

GeoVax Labs, Inc. (NASDAQ:GOVX – Free Report) – Investment analysts at Roth Capital issued their FY2029 EPS estimates for shares of GeoVax Labs in a research note issued on Friday, March 28th.

Good afternoon. And welcome everyone to the GeoVax Fourth Quarter Full Year 2024 Corporate Update Call. My name is Michelle and I will facilitate today’s call. With me are David Dodd ...